MARKER FOR DIAGNOSING KIDNEY DISEASE AND DIAGNOSTIC METHOD

• Main Authors: MO JINHUA, LI SHUNMIN, CHEN ZHI'AN, SHEN DONGTING, HAN PENGXUN, DONG NAIPING, SUN HUILI, GE NA
• Format: Patent
• Language: Chinese; English
• Published: 08.02.2022
• Subjects: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; PHYSICS; TESTING

Provided are a marker for diagnosing kidney disease and a diagnostic method. The method comprises: determining and analyzing the level of the marker in a sample from a subject, and diagnosing the progression stage of kidney disease in the subject, wherein the marker comprises at least one selected from succinyl adenosine, pseudouridine, N,N,N-trimethyl-L-alanyl-L-proline betaine, 2-(alpha-D-mannopyranosyl)-L-tryptophan, 4-acetamidobutyric acid, sulfotyrosine and 1,5-anhydro-D-sorbitol, and cooperates with creatinine to form a combined marker to form a combination of at least two markers, thereby improving errors caused by the current clinical reliance on creatinine to estimate GFR, and a situation where the quantitative detection of urine albumin is inaccurate. 本公开涉及诊断肾病的标志物以及诊断方法。该方法包括以下步骤：测定及分析来自所述受试者的样品中的标志物的水平，以诊断所述受试者的肾病发展分期。其中，所述标志物包括选自琥珀酰腺苷、假尿苷、N,N,N-三甲基-L-丙氨酰-L-脯氨酸甜菜碱、2-(α-D-吡喃甘露糖基)-L-色氨酸、4-乙酰氨基丁酸、磺基酪氨酸和1,5-脱水-D-山梨糖醇组成的组中的至少一种，并配合肌酐成联合标志物，组成至少两个标志物的组合，以改善现时临床依赖肌酐估算GFR造成的误差以及尿白蛋白定量检测难测准的情况。